Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 3Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Colorectal Neoplasms 2Stomach Neoplasms 1Rhabdomyosarcoma 1Neuroectodermal Tumors 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Fanconi Anemia 1Esophageal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 37Carboplatin 26Radiotherapy 23Cisplatin 19Paclitaxel 18Erlotinib Hydrochloride 18Docetaxel 15Gemcitabine 14Pemetrexed 13Etoposide 12osimertinib 11Nivolumab 11durvalumab 9atezolizumab 9Radiosurgery 8Magnetic Resonance Spectroscopy 8Cetuximab 7Specimen Handling 6Cyclophosphamide 6130-nm albumin-bound paclitaxel 6Taxes 5Immunoglobulin G 5Gefitinib 5Biopsy 5Bevacizumab 5fludarabine 4Radiation 4Ipilimumab 4Disulfides 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lung Neoplasms × Afatinib × Clear all
NCT02768337 2024-01-31

CamBMT1

Cambridge University Hospitals NHS Foundation Trust

Phase 1/2 Terminated
26 enrolled
BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡